Levetiracetam Solution
Product Images NDC 63629-9615

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 63629-9615). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image-01 (Image 01)

Chemical structure of levetiracetam, showing a pyrrolidone ring attached to an ethyl group and an amide group. The structure highlights the molecular geometry of the active ingredient levetiracetam.*

FDA Label Image

Label (Lbl636299615)

Levetiracetam Oral Solution, USP, 100 mg/mL, in a 473 mL container. The product is labeled as prescription only and includes storage instructions and pharmacist guidance. It is relabeled by Bryant Ranch Prepack, Inc. and manufactured by InvaTech Pharma Solutions, LLC. Several barcodes and a QR code are present on the label.*

FDA Label Image

Image-02 (Levetiracetam Fig1)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1' comparing the percentage of patients across three groups: Placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). The chart notes statistical significance of Levetiracetam groups versus placebo.*

FDA Label Image

Image-01 (Levetiracetam Fig2)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' comparing the percentage of patients responding to placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The chart shows responder rates of 6.3% for placebo, 20.8% for Levetiracetam 1000 mg/day, and 35.2% for Levetiracetam 2000 mg/day, with statistical significance indicated for both Levetiracetam groups versus placebo.*

FDA Label Image

Image-03 (Levetiracetam Fig3)

Bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' comparing percentage of patients achieving this response with placebo versus Levetiracetam 3000 mg/day. Placebo response is 14.4% and Levetiracetam 39.4%, with a note indicating statistical significance versus placebo.*

FDA Label Image

Image-04 (Levetiracetam Fig4)

A bar graph comparing responder rates (≥ 50% reduction from baseline) between placebo and Levetiracetam groups in Study 4. The Levetiracetam group shows a higher responder rate (44.6%) than the placebo group (19.6%), with a noted statistical significance.*

FDA Label Image

Image-05 (Levetiracetam Fig5)

A bar graph displaying the responder rate for patients ages 1 month to under 4 years in Study 5, showing the percentage of patients with at least 50% reduction from baseline. The graph compares placebo (19.6% responder rate, N=51) to Levetiracetam (43.1% responder rate, N=58), with Levetiracetam marked as statistically significant versus placebo.*

FDA Label Image

Image-06 (Levetiracetam Fig6)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7' comparing the percentage of patients for placebo (45.2%) and Levetiracetam (72.2%). The y-axis represents the percentage of patients from 0% to 100%, with sample sizes noted as N=84 for placebo and N=79 for Levetiracetam. Asterisk indicates statistical significance versus placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.